Canopy Growth stock analysis
Canopy Growth (CGC) Stock Price & Analysis
CGC Stock Chart & Stats
- Day’s Range
- $0.56 - $0.60
- 52-Week Range
- $0.56 - $2.38
- Previous Close
- $0.61
- Volume
- N/A
- Average Volume (3M)
- 2.68M
- Market Cap
- $277.58M
- Enterprise Value
- $494.26M
- Total Cash (Recent Filing)
- $319.79M
- Total Debt (Recent Filing)
- $281.44M
- Price to Earnings (P/E)
- ―
- Beta
- 1.53
- Next Earnings
- Feb 05, 2027 (Est.)
- EPS Estimate
- -0.04
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Broad Revenue Growth
Broad-based revenue growth indicates improving demand across Canopy’s portfolio rather than reliance on one product or market. Continued expansion in regulated cannabis channels can strengthen scale, support brand investment, and improve operating leverage over the next several quarters.
European Market Access
End-to-end EU GMP certification strengthens Canopy’s ability to supply regulated European markets and expand beyond flower into patient-ready products. This operational qualification can create a durable market-access advantage as international medical cannabis demand develops and product registrations broaden.
Improved Balance Sheet
Materially lower leverage and positive equity provide greater financial flexibility than in prior years. A healthier capital structure gives Canopy more capacity to fund cultivation improvements, execute operating initiatives, and withstand continued investment needs while pursuing a path toward profitability.
Bears Say
Persistent Operating Losses
Severe operating and net losses show that Canopy’s current cost structure remains far from sustainable profitability. Even with recent restructuring progress, the company must achieve meaningful scale, efficiency, and margin improvement before revenue growth can translate into durable earnings.
Ongoing Cash Burn
Negative operating and free cash flow mean the business is not yet funding itself internally. Persistent cash consumption can limit investment flexibility, increase reliance on available liquidity or financing, and make execution of cultivation and distribution initiatives more financially demanding.
Cost And Margin Pressure
The reimbursement-rate reduction demonstrates that external channel economics can materially compress margins in Canada Medical. Lower gross profitability reduces the benefit of revenue growth and increases the importance of product mix, cost control, and successful operational improvements.
Canopy Growth News
CGC FAQ
What was Canopy Growth’s price range in the past 12 months?
What is Canopy Growth’s market cap?
When is Canopy Growth’s upcoming earnings report date?
How were Canopy Growth’s earnings last quarter?
Is Canopy Growth overvalued?
Does Canopy Growth pay dividends?
What is Canopy Growth’s EPS estimate?
How many shares outstanding does Canopy Growth have?
What happened to Canopy Growth’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Canopy Growth?
What is the TipRanks Smart Score and how is it calculated?
Canopy Growth Stock Smart Score
Company Description
Canopy Growth
Canopy Growth Corporation, through its various operating units, is actively involved in the cultivation, marketing, and distribution of cannabis and hemp-derived products. These offerings serve both recreational consumers and medical patients across key markets including Canada, the United States, and Germany. The company's business activities are structured into two main divisions: its global cannabis operations and its diverse portfolio of other consumer goods. Its extensive product line features dried cannabis flower, a variety of extracts and concentrates, beverages, edible gummies, and vaporization products. Canopy Growth commercializes these goods under numerous well-known brands such as Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra. Formed in 2009, the enterprise initially operated as Tweed Marijuana Inc. before adopting its current name, Canopy Growth Corporation, in September 2015. Its principal office is located in Smiths Falls, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Luc Mongeau
- Employees
- 1,128
- Website
- www.canopygrowth.com
- Address
- 1 Hershey Drive, Smiths Falls, ON, K7A 0A8, CA
Canopy Growth (CGC) Earnings & Revenues
CGC Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive. Canopy reported strong consolidated, cannabis, international, medical, and adult-use revenue growth; improved operating efficiency; a narrower adjusted EBITDA loss; substantial liquidity; and progress in cultivation, EU GMP certification, and international expansion. The main negative factors were the 44% decline in Storz & Bickel revenue, lower consolidated gross margin due primarily to the Veteran Affairs Canada reimbursement-rate reduction, ongoing negative adjusted EBITDA, and the company's acknowledgment that cultivation costs are not yet best in class. Management nevertheless expressed confidence in achieving positive adjusted EBITDA in the second half of fiscal 2027 and in realizing further benefits from cultivation and operating initiatives.
View all CGC earnings summariesCGC Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |
